Skip to content

Evaluation of Quality-of-Life Improvements Using UroShield Device

Evaluation of Quality-of-Life Improvements Using UroShield for Patients Living in Long Term Care Facilities With Indwelling Urinary Catheters - A Pilot Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06319352
Enrollment
18
Registered
2024-03-20
Start date
2024-04-29
Completion date
2024-11-01
Last updated
2026-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-Associated Urinary Tract Infection, Quality of Life

Brief summary

The goal of this pilot study is to test key elements of the full study that will follow, including recruitment and retention strategies, intervention delivery, laboratory testing, data collection methods, and adherence to study protocol. The main questions the investigators aim to answer focus on implementation and practicality: * Recruitment feasibility and time to recruit * How well do participants adhere to device protocol? * How often do device components (i.e., actuators and drivers) have to be replaced? * How much time is required for data collection and what sources or methods for data collection are used? Results of this pilot study will inform the investigators as to necessary protocol modifications and overall feasibility for the larger randomized clinical trial to follow.

Detailed description

The UroShield® device works by generating ultrasonic waves to interfere with attachment of bacteria inside the catheter, preventing biofilm formation and subsequent infections. This double-blind pilot study aims to recruit 10-20 participants with urinary catheters (urethral or suprapubic catheters) living in nursing homes (NHs) in Michigan. Participants providing consent will be randomized to either the treatment or control group and will have either an active treatment UroShield® device attached or a sham UroShield® device attached to the external tubing of their urinary catheter. Participants will wear the device continuously for a maximum of 90 days. Assessments of pain and quality-of-life will be conducted by study staff over a maximum of 6 study visits, along with clinical data collection via medical record review. A urine sample and catheter sample will also be collected by study staff at each catheter change (approximately every 30 days).

Interventions

DEVICEActive UroShield

Participants will have an active device (i.e., ultrasound energy is being produced by actuator) attached to their urinary catheter tube.

Participants will have an inactive device (i.e., no ultrasound energy being produced by the actuator) attached to their urinary catheter tube. All other aspects of the sham device (look, weight, feel, sound, and operation) are identical to the active device.

Sponsors

University of Michigan
Lead SponsorOTHER
Nanovibronix
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DEVICE_FEASIBILITY
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male or female age 18+ * Indwelling urinary catheter (urethral or suprapubic) in place * Written informed consent (and assent, when applicable) obtained from participant or participant's legal representative * Able to comply with the requirements of the study

Exclusion criteria

* Pregnant or breastfeeding women * Antibiotic use in past 10 days * Ineligible catheter type in place (e.g., antimicrobial coated, 3-way catheter, condom catheter, nephrostomy tube, wicking device) * Participation in another drug or device study in past 30 days * History of poor compliance to medical treatment regimens * Conditions that may severely compromise their ability to complete the study

Design outcomes

Primary

MeasureTime frameDescription
Feasibility as Measured by Recruitment rateSummarized every month for 6 months, or until the recruitment goal is reached.Feasibility was determined by the number of participants enrolled out of the number of participants eligible to participate in the study.

Secondary

MeasureTime frameDescription
Device use adherenceSummarized every month for at least 6 months, or until the recruitment goal is reached.Number of patients with at least 80% adherence out of total patients enrolled. Device adherence will be assessed via direct observation by study staff as well as patient/caregiver/clinician-reported (via written documentation or phone/email correspondence).
Device accountabilitySummarized every month for at least 6 months, or until the recruitment goal is reached.Number of devices used out of the number of devices received. Extra components of the device (i.e., actuators) will be available to the study team; monitoring their use will validate amount and type of resources needed for intervention implementation.
Efficiency of data collectionSummarized every month for at least 6 months, or until the recruitment goal is reached.Time required for survey completion and data abstraction via chart review (actual time/expected time).

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLona Mody

University of Michigan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026